Precision Medicine in Oncology®

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

The John Theurer Cancer Center is proud to be partnering with Intellisphere to advance this mission by overseeing editorial content development and helping to provide in-depth content, new learning opportunities, and bestpractice approaches to cancer care.

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Dr. Robert Alter on Current Research at John Theurer Cancer Center

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Gives Advice for Newly Diagnosed Kidney Cancer Patients

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses what Separates MSKCC From Other Top Cancer Centers Worldwide

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Genomics and Personalized Medicine

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

The Sylvester Comprehensive Cancer Center (SCCC), part of the University of Miami Health System, first opened its doors in 1992. Over the years, the SCCC has become the hub of cancer research in the region.

In 1974 the National Cancer Institute designated Yale Cancer Center as one of the country's inaugural comprehensive cancer centers.

The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer, and more

Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more

The Clinical Trials reported include: PHASE III: 1) Is Combination or Sequential Treatment for Metastatic Colorectal Cancer More Effective? 2) Cervical Cancer Vaccines Do Not Work Like Investigational Cancer Vaccines, Study Confirms 3) Docetaxel to Improve Clinical and Quality of Life Improvement in the Treatment of Advanced Gastric or Gastroesophageal Cancer, and more

The Clinical Trials Reported in this issue include: PHASE III: 1) Trastuzumab and Anastrozole Extend Breast Cancer Survival in Patients Who Received Anastrozole Alone Earlier PHASE II: 1) Motexafin for Non%u2013Small Cell Lung Cancer 2) Oral Satraplatin Monotherapy for the Treatment of Metastatic Breast Cancer Shows Little Response, and more

Clinical trials covered include: 1) Phase III: Quality of Life with Sunitinib or Interferon Alfa for Patients with Metastatic Renal Cell Carcinoma 2) Phase II: Children%u2019s Oncology Group Pilot Study, and more

It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.

Some of the Top Health IT Stories from 2008 are discussed.

Currently available pharmaceutical therapies for many chronic illnesses leave much to be desired.